Autologous hematopoietic stem cell transplantation for treatment of multiple myeloma patients with renal impairment / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma (MM) is a common hematological malignancy with renal impairment in approximately 50% of patients. Sever renal impairment occurs in 15%-20% of newly diagnosed multiple myeloma patients. 200 mg/m2 melphalan-based regimen (Mel 200 regimen) as conditioning regimen of autologous hematopoietic stem cell transplantation (AHCT) is suitable for multiple myeloma patients with mild or moderate renal impairment, and 400 mg/m2 melphalan-based regimen (Mel 140 regimen) is fit for multiple myeloma patients with severe renal impairment. As the first line therapy for multiple myeloma patients with renal impairment, AHCT can increase response depth, repair renal function and improve survival. AHCT is a safe and beneficial procedure for MM patients with renal failure.